Aligos Therapeutics Reports Promising HBV and COVID-19 Data at CROI 2026
Event summary
- Aligos Therapeutics presented positive Phase 1 data for pevifoscorvir sodium, a CAM-E for chronic HBV, at CROI 2026.
- ALG-097558, a pan-coronavirus protease inhibitor, showed promising pharmacokinetics in renal and hepatic impairment participants.
- The ALG-097558 project was funded in part by the NIH under Contract No. 75N93023C00052.
- Presentations were held on February 23 and 25, 2026, in Denver, Colorado.
The big picture
Aligos Therapeutics' presentations at CROI 2026 highlight its dual focus on chronic HBV and pan-coronavirus treatments, aligning with the growing demand for innovative solutions in viral disease management. The company's ability to secure NIH funding underscores the strategic importance of its pipeline, particularly in the context of ongoing public health challenges. The data presented could position Aligos as a key player in both HBV and broad-spectrum antiviral therapies.
What we're watching
- Clinical Progress
- How the Phase 1 data for pevifoscorvir sodium will impact Aligos' strategic positioning in the HBV treatment landscape.
- Regulatory Pathway
- Whether the positive ALG-097558 data accelerates regulatory discussions for its pan-coronavirus application.
- Funding Dynamics
- The pace at which Aligos can secure additional government or private funding for its COVID-19 and HBV programs.
Related topics